Department of Neurosciences, Medical University of South Carolina, Charleston, SC 29425, USA.
Pharmacol Ther. 2009 Nov;124(2):235-47. doi: 10.1016/j.pharmthera.2009.06.014. Epub 2009 Aug 13.
Addiction is a chronic relapsing brain disease and treatment of relapse to drug-seeking is considered the most challenging part of treating addictive disorders. Relapse can be modeled in laboratory animals using reinstatement paradigms, whereby behavioral responding for a drug is extinguished and then reinstated by different trigger factors, such as environmental cues or stress. In this review, we first describe currently used animal models of relapse, different relapse triggering factors, and the validity of this model to assess relapse in humans. We further summarize the growing body of pharmacological interventions that have shown some promise in treating relapse to psychostimulant addiction. Moreover, we present an overview on the drugs tested in cocaine or methamphetamine addicts and examine the overlap of existing preclinical and clinical data. Finally, based on recent advances in our understanding of the neurobiology of relapse and published preclinical data, we highlight the most promising areas for future anti-relapse medication development.
成瘾是一种慢性复发性脑部疾病,治疗觅药复发被认为是治疗成瘾障碍最具挑战性的部分。可以使用重新激发范式在实验室动物中对复发进行建模,其中通过不同的触发因素(例如环境线索或压力)来消除和重新激发对药物的行为反应。在这篇综述中,我们首先描述了目前用于复发的动物模型、不同的复发触发因素以及该模型评估人类复发的有效性。我们进一步总结了在治疗精神兴奋剂成瘾的复发方面显示出一定前景的越来越多的药理学干预措施。此外,我们介绍了可卡因或甲基苯丙胺成瘾者中测试的药物,并检查了现有临床前和临床数据的重叠。最后,根据我们对复发神经生物学的最新理解和已发表的临床前数据,我们突出了未来抗复发药物开发最有希望的领域。